A non-interventional observational study in adults and children from 5 years of age assessing the safety and tolerability of GRAZAX® in case of concomitant specific immunotherapy (SCIT or SLIT)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005009

Enrollment

300

Registered

2013-05-22

Start date

2012-01-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

grass pollen induced allergic rhinoconjunctivitis J30.1

Interventions

Group 1: routine treatment with grass immunotherapy tablet (grass AIT, GRAZAX) and concomitant further specific immunothereapy, documentation of tolerability

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: The tolerability of the grass immunotherapy tablet (GRAZAX) during routine treatment is recorded in children and adults who are treated concomitantly with additional specific immunotherapy for treatment of further allergies.

Exclusion criteria

Exclusion criteria: Contraindications of specific immunotherapy

Design outcomes

Primary

Measure	Time frame
Frequency and type of adverse events recorded by the physician at first application and in patient diaries during home treatment coded acc. to MedDRA	—

Secondary

Measure	Time frame
Global assessment of tolerability by physician and patient	—

Countries

Germany

Contacts

Public ContactHendrik Wolf

ALK-Abelló Arzneimittel GmbH, Clinical Development

hendrik.wolf@alk.net+49 40 703845-342

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026